You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 7, July 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Radiology of Head & Neck
 •Radiation Therapy
 •Alert me on articles by topic

Retromolar Trigone Carcinoma Treated by Primary Radiation Therapy

An Alternative to the Primary Surgical Approach

Tareck Ayad, MD; Michel Gélinas, MD; Louis Guertin, MD; Daniel Larochelle, MD; Pierre Del Vecchio, MD; Jean-Claude Tabet, MD; Marie-Jo Olivier, MD; Denis Soulières, MD; Danielle Charpentier, MD; Phuc Félix Nguyen-Tân, MD

Arch Otolaryngol Head Neck Surg. 2005;131:576-582.

Objectives  To review our experience in the treatment of retromolar trigone carcinoma with radiotherapy as the primary modality and to evaluate the different factors affecting locoregional control and survival.

Design  We retrospectively examined 46 patients with squamous cell carcinoma of the retromolar trigone treated primarily with radiotherapy from January 1, 1973, to June 31, 2002. Four had T1, 21 had T2, 17 had T3, and 4 had T4 lesions; 25 had N0, 15 had N1, 5 had N2, and 1 had N3 disease. The overall stage was I in 3, II in 18, III in 18, and IV in 7 patients. All patients received conventional once-daily fraction radiotherapy as the primary modality of treatment. Three patients received chemotherapy. Overall survival, cause-specific survival, and locoregional control were estimated using the Kaplan-Meier method. Log-rank statistics were used to identify significant prognostic factors for overall survival and locoregional control.

Results  The median follow-up was 43 (range, 5-217) months overall and 78 (range, 26-188) months for living patients. The 5-year overall survival and cause-specific survival rates were 47% and 78%, respectively. Favorable prognostic factors for cause-specific survival were a lower tumor stage (univariate and multivariate analysis) and a lower nodal stage (multivariate analysis). The 5-year local control rate was 49% after radiotherapy and 67% after salvage surgery. The 5-year regional control rate was 88%. Favorable prognostic factors were a lower nodal stage and a lower overall stage (univariate analysis). The 5-year locoregional control rate for all patients was 42% after radiotherapy and 70% after salvage surgery.

Conclusions  Given the surgical salvage rate in our series and previous published experience, radiation therapy can be used with curative intent for small retromolar trigone carcinomas (T1-T2 lesions). For advanced stages without bone invasion, consideration for concurrent chemotherapy and radiation therapy might increase previous historical locoregional and survival rates.


Author Affiliations: Departments of Otolaryngology and Head and Neck Surgery (Drs Ayad, Guertin, Larochelle, Tabet, and Olivier), Radiation Oncology (Drs Gélinas, Del Vecchio, and Nguyen-Tân), and Hematology-Oncology (Drs Soulières and Charpentier), Notre-Dame Hospital, Montreal, Quebec.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.